BUZZ-Brokerage Perspective: Micron Temporarily Eases Supply Concerns, Growth Becomes the Focus
路透社2026/10/01 11:31October 1 - ** Micron Technology MU.O on Wednesday reported quarterly revenue (link) that exceeded Wall Street expectations, and said that the total value of customer orders under long-term supply agreements has risen to $32 billion, highlighting strong demand for AI memory chips.
** The median target price from 49 brokers covering the stock is $1,535 — according to data compiled by London Stock Exchange Group (LSEG).
Supply concerns ease
** Morgan Stanley (rating: “Overweight”, target price: $1,200) said that Micron Technology has clear visibility on its share of industry growth and that its latest guidance should help alleviate market concerns about rising supply.
** JPMorgan (“Overweight”, target price: $1,540) pointed out that MU’s strong earnings beats and raised guidance, expanded supply coverage, and tightening supply-demand outlook all reinforce expectations for multi-year earnings growth.
** TD Cowen (“Buy”, target price: $1,600) noted that Micron Technology (MU) will benefit from AI-driven growth in memory demand, especially for CPU memory used by AI agents, while this potential upside is not yet reflected in the signed long-term agreements.
** Morningstar (fair value: $700) “believes that Micron’s (HBM, high-bandwidth memory) share of total shipments and revenue will continue to grow, supporting performance growth and margins.”
(To assist non-English speakers, Reuters has automatically translated its report into several other languages. Automated translation may contain errors or lack required context, so Reuters does not guarantee the accuracy of the translated text. Automated translation is provided solely for reader convenience. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation functionality.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Stifel initiates coverage, Immunome stock rises
ZenaTech joins Russell 3000 Index
BUZZ-Evommune shares rise as its eczema drug meets mid-stage trial targets